The loop diuretic torasemide but not azosemide potentiates the anti-seizure and disease-modifying effects of midazolam in a rat model of birth asphyxia
Epilepsy Behav. 2022 Dec 29;139:109057. doi: 10.1016/j.yebeh.2022.109057. Online ahead of print.ABSTRACTLoop diuretics such as furosemide and bumetanide, which act by inhibiting the Na-K-2Cl cotransporter NKCC2 at the thick ascending limb of the loop of Henle, have been shown to exert anti-seizure effects. However, the exact mechanism of this effect is not known. For bumetanide, it has been suggested that inhibition of the NKCC isoform NKCC1 in the membrane of brain neurons may be involved; however, NKCC1 is expressed by virtually all cell types in the brain, which makes any specific targeting of neuronal NKCC1 by bumetani...
Source: Epilepsy and Behaviour - December 31, 2022 Category: Neurology Authors: Bj örn Welzel Ricardo Schmidt Larsen Kirchhoff Martina Gramer Wolfgang L öscher Source Type: research
A new role for an old drug: acetazolamide in decompensated heart failure
This article discusses ADVOR. The primary endpoint of ADVOR was the reversal of congestion, which was increased by adding acetazolamide to bumetanide. However, acetazolamide did not shorten hospital stay or the composite of rehospitalisation and death after three months.EXPERT OPINION: The limitations of ADVOR include that acetazolamide did not improve quality of life and that the testing was in white subjects only. During the hospital stay for decompensation, medicines that inhibit the angiotensin and mineralocorticoid systems were increased, which suggests that the treatment for heart failure was not ideal on hospitaliza...
Source: Expert Opinion on Pharmacotherapy - December 23, 2022 Category: Drugs & Pharmacology Authors: Sheila A Doggrell Source Type: research
A new role for an old drug: Acetazolamide in decompensated heart failure
This article discusses ADVOR. The primary endpoint of ADVOR was the reversal of congestion, which was increased by adding acetazolamide to bumetanide. However, acetazolamide did not shorten hospital stay or the composite of rehospitalisation and death after three months.EXPERT OPINION: The limitations of ADVOR include that acetazolamide did not improve quality of life and that the testing was in white subjects only. During the hospital stay for decompensation, medicines that inhibit the angiotensin and mineralocorticoid systems were increased, which suggests that the treatment for heart failure was not ideal on hospitalisa...
Source: Expert Opinion on Pharmacotherapy - December 23, 2022 Category: Drugs & Pharmacology Authors: Sheila A Doggrell Source Type: research
A new role for an old drug: acetazolamide in decompensated heart failure
This article discusses ADVOR. The primary endpoint of ADVOR was the reversal of congestion, which was increased by adding acetazolamide to bumetanide. However, acetazolamide did not shorten hospital stay or the composite of rehospitalisation and death after three months.EXPERT OPINION: The limitations of ADVOR include that acetazolamide did not improve quality of life and that the testing was in white subjects only. During the hospital stay for decompensation, medicines that inhibit the angiotensin and mineralocorticoid systems were increased, which suggests that the treatment for heart failure was not ideal on hospitaliza...
Source: Expert Opinion on Pharmacotherapy - December 23, 2022 Category: Drugs & Pharmacology Authors: Sheila A Doggrell Source Type: research
A new role for an old drug: Acetazolamide in decompensated heart failure
This article discusses ADVOR. The primary endpoint of ADVOR was the reversal of congestion, which was increased by adding acetazolamide to bumetanide. However, acetazolamide did not shorten hospital stay or the composite of rehospitalisation and death after three months.EXPERT OPINION: The limitations of ADVOR include that acetazolamide did not improve quality of life and that the testing was in white subjects only. During the hospital stay for decompensation, medicines that inhibit the angiotensin and mineralocorticoid systems were increased, which suggests that the treatment for heart failure was not ideal on hospitalisa...
Source: Expert Opinion on Pharmacotherapy - December 23, 2022 Category: Drugs & Pharmacology Authors: Sheila A Doggrell Source Type: research
A new role for an old drug: acetazolamide in decompensated heart failure
This article discusses ADVOR. The primary endpoint of ADVOR was the reversal of congestion, which was increased by adding acetazolamide to bumetanide. However, acetazolamide did not shorten hospital stay or the composite of rehospitalisation and death after three months.EXPERT OPINION: The limitations of ADVOR include that acetazolamide did not improve quality of life and that the testing was in white subjects only. During the hospital stay for decompensation, medicines that inhibit the angiotensin and mineralocorticoid systems were increased, which suggests that the treatment for heart failure was not ideal on hospitaliza...
Source: Expert Opinion on Pharmacotherapy - December 23, 2022 Category: Drugs & Pharmacology Authors: Sheila A Doggrell Source Type: research
A new role for an old drug: Acetazolamide in decompensated heart failure
This article discusses ADVOR. The primary endpoint of ADVOR was the reversal of congestion, which was increased by adding acetazolamide to bumetanide. However, acetazolamide did not shorten hospital stay or the composite of rehospitalisation and death after three months.EXPERT OPINION: The limitations of ADVOR include that acetazolamide did not improve quality of life and that the testing was in white subjects only. During the hospital stay for decompensation, medicines that inhibit the angiotensin and mineralocorticoid systems were increased, which suggests that the treatment for heart failure was not ideal on hospitalisa...
Source: Expert Opinion on Pharmacotherapy - December 23, 2022 Category: Drugs & Pharmacology Authors: Sheila A Doggrell Source Type: research
A new role for an old drug: acetazolamide in decompensated heart failure
This article discusses ADVOR. The primary endpoint of ADVOR was the reversal of congestion, which was increased by adding acetazolamide to bumetanide. However, acetazolamide did not shorten hospital stay or the composite of rehospitalisation and death after three months.EXPERT OPINION: The limitations of ADVOR include that acetazolamide did not improve quality of life and that the testing was in white subjects only. During the hospital stay for decompensation, medicines that inhibit the angiotensin and mineralocorticoid systems were increased, which suggests that the treatment for heart failure was not ideal on hospitaliza...
Source: Expert Opinion on Pharmacotherapy - December 23, 2022 Category: Drugs & Pharmacology Authors: Sheila A Doggrell Source Type: research
A new role for an old drug: Acetazolamide in decompensated heart failure
This article discusses ADVOR. The primary endpoint of ADVOR was the reversal of congestion, which was increased by adding acetazolamide to bumetanide. However, acetazolamide did not shorten hospital stay or the composite of rehospitalisation and death after three months.EXPERT OPINION: The limitations of ADVOR include that acetazolamide did not improve quality of life and that the testing was in white subjects only. During the hospital stay for decompensation, medicines that inhibit the angiotensin and mineralocorticoid systems were increased, which suggests that the treatment for heart failure was not ideal on hospitalisa...
Source: Expert Opinion on Pharmacotherapy - December 23, 2022 Category: Drugs & Pharmacology Authors: Sheila A Doggrell Source Type: research
A new role for an old drug: acetazolamide in decompensated heart failure
This article discusses ADVOR. The primary endpoint of ADVOR was the reversal of congestion, which was increased by adding acetazolamide to bumetanide. However, acetazolamide did not shorten hospital stay or the composite of rehospitalisation and death after three months.EXPERT OPINION: The limitations of ADVOR include that acetazolamide did not improve quality of life and that the testing was in white subjects only. During the hospital stay for decompensation, medicines that inhibit the angiotensin and mineralocorticoid systems were increased, which suggests that the treatment for heart failure was not ideal on hospitaliza...
Source: Expert Opinion on Pharmacotherapy - December 23, 2022 Category: Drugs & Pharmacology Authors: Sheila A Doggrell Source Type: research
Efficacy of the anti-seizure medications in acute symptomatic neonatal seizures caused by stroke. A systematic review
CONCLUSIONS: Our review shows that the use of ASMs that act throughout a gabaergic mechanism are inadequate in controlling seizures secondary to neonatal stroke in full-term newborns. Very effective seems to be lidocaine and levetiracetam with an apparent safer profile in short and long term. Bumetanide shows promising results, but they need to be confirmed by phase 3 studies.PMID:36533757 | DOI:10.23750/abm.v93i6.13440 (Source: Acta Bio-Medica : Atenei Parmensis)
Source: Acta Bio-Medica : Atenei Parmensis - December 19, 2022 Category: General Medicine Authors: Vincenzo Sortino Andrea Pratic ò Silvia Marino Roberta Criscione Martino Ruggieri Francesco Pisani Raffaele Falsaperla Source Type: research
Efficacy of the anti-seizure medications in acute symptomatic neonatal seizures caused by stroke. A systematic review
CONCLUSIONS: Our review shows that the use of ASMs that act throughout a gabaergic mechanism are inadequate in controlling seizures secondary to neonatal stroke in full-term newborns. Very effective seems to be lidocaine and levetiracetam with an apparent safer profile in short and long term. Bumetanide shows promising results, but they need to be confirmed by phase 3 studies.PMID:36533757 | DOI:10.23750/abm.v93i6.13440 (Source: Acta Bio-Medica : Atenei Parmensis)
Source: Acta Bio-Medica : Atenei Parmensis - December 19, 2022 Category: General Medicine Authors: Vincenzo Sortino Andrea Pratic ò Silvia Marino Roberta Criscione Martino Ruggieri Francesco Pisani Raffaele Falsaperla Source Type: research
Efficacy of the anti-seizure medications in acute symptomatic neonatal seizures caused by stroke. A systematic review
CONCLUSIONS: Our review shows that the use of ASMs that act throughout a gabaergic mechanism are inadequate in controlling seizures secondary to neonatal stroke in full-term newborns. Very effective seems to be lidocaine and levetiracetam with an apparent safer profile in short and long term. Bumetanide shows promising results, but they need to be confirmed by phase 3 studies.PMID:36533757 | DOI:10.23750/abm.v93i6.13440 (Source: Acta Bio-Medica : Atenei Parmensis)
Source: Acta Bio-Medica : Atenei Parmensis - December 19, 2022 Category: General Medicine Authors: Vincenzo Sortino Andrea Pratic ò Silvia Marino Roberta Criscione Martino Ruggieri Francesco Pisani Raffaele Falsaperla Source Type: research
Efficacy of the anti-seizure medications in acute symptomatic neonatal seizures caused by stroke. A systematic review
CONCLUSIONS: Our review shows that the use of ASMs that act throughout a gabaergic mechanism are inadequate in controlling seizures secondary to neonatal stroke in full-term newborns. Very effective seems to be lidocaine and levetiracetam with an apparent safer profile in short and long term. Bumetanide shows promising results, but they need to be confirmed by phase 3 studies.PMID:36533757 | DOI:10.23750/abm.v93i6.13440 (Source: Acta Bio-Medica : Atenei Parmensis)
Source: Acta Bio-Medica : Atenei Parmensis - December 19, 2022 Category: General Medicine Authors: Vincenzo Sortino Andrea Pratic ò Silvia Marino Roberta Criscione Martino Ruggieri Francesco Pisani Raffaele Falsaperla Source Type: research
